Progressive Familial Intrahepatic Cholestasis Market Analysis of Epidemiology, Pipeline Therapies, and Key Companies Working in the Market

September 26 19:34 2022
Progressive Familial Intrahepatic Cholestasis Market Analysis of Epidemiology, Pipeline Therapies, and Key Companies Working in the Market
Progressive Familial Intrahepatic Cholestasis Market
DelveInsight’s “Progressive Familial Intrahepatic Cholestasis (PFIC) Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Progressive Familial Intrahepatic Cholestasis (PFIC), historical and forecasted epidemiology as well as the Progressive Familial Intrahepatic Cholestasis (PFIC) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

DelveInsight’s “Progressive Familial Intrahepatic Cholestasis (PFIC) Market Insights, Epidemiology, and Market Forecast-2032″  report delivers an in-depth understanding of the Progressive Familial Intrahepatic Cholestasis (PFIC), historical and forecasted epidemiology as well as the Progressive Familial Intrahepatic Cholestasis (PFIC) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

The Progressive Familial Intrahepatic Cholestasis (PFIC) market report provides current treatment practices, emerging drugs, Progressive Familial Intrahepatic Cholestasis (PFIC) market share of the individual therapies, current and forecasted Progressive Familial Intrahepatic Cholestasis (PFIC) market Size from 2019 to 2032 segmented by seven major markets. The Report also covers current Progressive Familial Intrahepatic Cholestasis (PFIC) treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Progressive Familial Intrahepatic Cholestasis (PFIC) market.

 

Some of the key facts of the Progressive Familial Intrahepatic Cholestasis Market Report:

  • According to Abdolreza et al. (2018), the most common clinical complaints of patients at diagnosis of TED were weight loss (35.9%), proptosis (31.1%), and cardiac palpitation (10.7%), with a statistically significant difference in the frequency of clinical complaints between men and women. The most common complaint in men was eye proptosis (42.9%), while in women it was weight loss (37%).
  • The pathophysiology of Thyroid eye disease is complex and incompletely understood
  • A study by Baker et al. [2019] reported that from 1990 to 2008, there were about 58, 66, 62, and 14 cases of PFIC in the US, Germany, France, and Japan, respectively.

Key benefits of the Progressive Familial Intrahepatic Cholestasis Market report:

  • The report covers the descriptive overview of Progressive Familial Intrahepatic Cholestasis (PFIC), explaining its causes, signs and symptoms, pathophysiology, diagnosis, and currently available therapies
  • Comprehensive insight has been provided into the Progressive Familial Intrahepatic Cholestasis (PFIC) epidemiology and treatment in the 7MM
  • Additionally, an all-inclusive account of both the current and emerging therapies for Progressive Familial Intrahepatic Cholestasis (PFIC) is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
  • A detailed review of the Progressive Familial Intrahepatic Cholestasis (PFIC) market; historical and forecasted is included in the report, covering drug outreach in the 7MM
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Progressive Familial Intrahepatic Cholestasis (PFIC) market

Got queries? Click here to know more about the Progressive Familial Intrahepatic Cholestasis  Market  Landscape

 

Progressive Familial Intrahepatic Cholestasis Overview

Diagnosis of PFIC is based on clinical manifestations, liver ultrasonography, cholangiography, genetic testing of liver and liver histology (biopsy), as well as on specific tests for excluding other causes of childhood cholestasis. MDR3 and BSEP liver immunostaining, and analysis of biliary lipid composition should help to select PFIC candidates in whom genotyping could be proposed to confirm the diagnosis.

 

Progressive Familial Intrahepatic Cholestasis Epidemiological Insight

  • As per the Children’s Liver Disease Foundation, PFIC affects
  • According to Progressive Familial Intrahepatic Cholestasis (PFIC) Organization, mortality rates reported in previous studies ranges from 0-87%. The high number (87%) is probably the mortality rate when PFIC is not treated. Causes of death include infections, liver failure, and complications related to liver transplants. 
  • The United Kingdom-based study conducted by Baker et al. [2019] found that the prevalence of intrahepatic cholestasis was 1 per 18,000 live births. The researchers also referred to a study in which infants and children (2–18 years) with cholestasis were 12–13% with genetically diagnosed PFIC.
  • According to a French study by Davit-Spraul et al. [2009], the estimated prevalence varies between 1 per 50,000 and 1 per 100,000 births in the PFIC patients. It was also found that PFIC1 and PFIC2 represented two out of three cases of total PFIC, whereas PFIC3 as one case per three cases.

Progressive Familial Intrahepatic Cholestasis Market  Epidemiological Segmentation 

  •  Progressive Familial Intrahepatic Cholestasis prevalent population 
  •  Progressive Familial Intrahepatic Cholestasis type-specific prevalence 
  •  Progressive Familial Intrahepatic Cholestasis diagnosed and Treatable Cases 

 

Progressive Familial Intrahepatic Cholestasis Market Outlook 

The Progressive Familial Intrahepatic Cholestasis (PFIC) market outlook of the report helps to build a detailed comprehension of the historic, current and forecasted Progressive Familial Intrahepatic Cholestasis (PFIC) market trends by analyzing the impact of current Progressive Familial Intrahepatic Cholestasis (PFIC) therapies on the market, unmet needs, drivers and barriers, and demand for better technology.

 

This segment gives a thorough detail of the Progressive Familial Intrahepatic Cholestasis (PFIC) market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Progressive Familial Intrahepatic Cholestasis (PFIC) market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

 

According to DelveInsight, the Progressive Familial Intrahepatic Cholestasis (PFIC) market in 7MM is expected to witness a major change in the study period 2019-2032.

 

Learn more by requesting for sample @Progressive Familial Intrahepatic Cholestasis Market Landscape

Progressive Familial Intrahepatic Cholestasis Key Companies  

  • Albireo Pharma 
  • Vivet Therapeutics
  • Mirum Pharmaceuticals
  • And others

 

Progressive Familial Intrahepatic Cholestasis Therapies 

  • ursodeoxycholic acid 
  • antihistamines, 
  • rifampin, and bile acid-binding agents.
  •  

Table of Contents

  • Key Insights 
  • Report Introduction 
  •  Executive Summary of Progressive Familial Intrahepatic Cholestasis
  •  Disease Background and Overview
  •  Epidemiology and patient population
  •  The United States 
  •  EU 5
  •  Progressive Familial Intrahepatic Cholestasis  Emerging Therapies
  • Progressive Familial Intrahepatic Cholestasis  Market Outlook
  •  Market Access and Reimbursement of Therapies
  • Appendix
  • Progressive Familial Intrahepatic Cholestasis  Report Methodology
  • DelveInsight Capabilities
  •  Disclaimer
  • About DelveInsight

Click here to read more about Progressive Familial Intrahepatic Cholestasis  Market

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Adya Kaul
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

  Categories: